Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients

Trial Profile

Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Palbociclib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PADA-1
  • Most Recent Events

    • 12 Jun 2018 According to trial design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology, as of January 2018, 426 patients have been enrolled.
    • 05 Jun 2018 Trial design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 19 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top